TY - JOUR T1 - A Phase I Study of Concurrent Chemoradiotherapy and Cetuximab for Locally Advanced Esophageal Cancer JF - Anticancer Research JO - Anticancer Res SP - 4019 LP - 4023 VL - 32 IS - 9 AU - CECILIE HOLLĂ„NDER AU - LENE BAEKSGAARD AU - MORTEN SORENSEN AU - PER ALBERTSSON AU - LARS DAMSTRUP AU - ULRIK LASSEN Y1 - 2012/09/01 UR - http://ar.iiarjournals.org/content/32/9/4019.abstract N2 - Aim: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer. Patients and Methods: Escalating doses of oxaliplatin every second week and daily tegafur/uracil were given concurrently with radiotherapy, 59.4 Gy in 33 fractions. Cetuximab was given on day 15 (400 mg/m2) and weekly (250 mg/m2) during radiotherapy. Fixed doses of oxaliplatin (130 mg/m2) and tegafur/uracil (300 mg/m2) were administered before, and after radiotherapy. Results: Eleven patients were included in the study; two were excluded due to allergic reactions to cetuximab. In DL2 (tegafur/uracil 300 mg/m2, oxaliplatin 30 mg/m2) two grade 3/4 fistula and one grade 3 neuropathy were observed. Six patients were enrolled in DL1 (tegafur/uracil 150 mg/m2/, oxaliplatin 30 mg/m2) with no DLTs. Four out of 9 patients had complete response. Conclusion: Concomitant chemoradiotherapy and cetuximab had significant activity. DL1 was established as the MTD. ER -